Momenta Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc.

MNTA 52.48

0.0%

Oct 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (3015)	10/4/2017 2:32:56 PM
From: tuck	Read Replies (1) of 3027

Wasn't there a bit of patent life left? i.e. if Mylan were to launch this very day, wouldn't they be doing so at risk? Can't remember where we were with that, and wondered if you or anyone knows the answer off the top of their heads. Mylan's PR suggested it might wait and avoid the fight, giving MNTA that much time to get it's fill/finish act together. Regardless, when you say multiple entrants, I assume you mean more than one. So if MNTA did get on the market, Teva would launch the authorized generic. Maybe they will do so first with 20mg dose, since there are now two of those. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next